Literature DB >> 24132645

Atrial fibrillation in heart failure: catheter and surgical interventional therapies.

Ali Rabah1, Oussama Wazni.   

Abstract

Atrial fibrillation and heart failure commonly coexist in the same patient. Each may adversely affect the other. Atrial fibrillation leads to heart failure exacerbation, left ventricular function deterioration and an increase in thrombo-embolic risk. Therapeutic options targeting atrial fibrillation in heart failure patients include pharmacological and non-pharmacological means. Pharmacological therapy is directed at either rate control using nodal blocking agents or rhythm control using anti-arrhythmic agents, of which the options are limited in patients with heart failure. The landmark AF-CHF trial did not show any benefit of rhythm control strategy as opposed to rate control in patients with heart failure and atrial fibrillation. However, patients in this trial as well as in others used mostly amiodarone for rhythm control. This might have negated any positive effects of achieving normal sinus rhythm. Non-pharmacological therapy both for rate and rhythm control is appealing. This includes AV node ablation for rate control, catheter ablation of atrial fibrillation and surgical therapy of atrial fibrillation. This review will address non-pharmacologic treatment of AF in heart failure patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24132645     DOI: 10.1007/s10741-013-9411-x

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.214


  50 in total

1.  Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation.

Authors:  D M Clark; V J Plumb; A E Epstein; G N Kay
Journal:  J Am Coll Cardiol       Date:  1997-10       Impact factor: 24.094

2.  The Cox maze procedure in mitral valve disease: predictors of recurrent atrial fibrillation.

Authors:  A Marc Gillinov; Jon Sirak; Eugene H Blackstone; Patrick M McCarthy; Jeevanantham Rajeswaran; Gosta Pettersson; F Joseph Sabik; Lars G Svensson; Jose L Navia; Delos M Cosgrove; Nassir Marrouche; Andrea Natale
Journal:  J Thorac Cardiovasc Surg       Date:  2005-10-26       Impact factor: 5.209

3.  Catheter ablation of long-lasting persistent atrial fibrillation: clinical outcome and mechanisms of subsequent arrhythmias.

Authors:  Michel Haïssaguerre; Mélèze Hocini; Prashanthan Sanders; Frederic Sacher; Martin Rotter; Yoshihide Takahashi; Thomas Rostock; Li-Fern Hsu; Pierre Bordachar; Sylvain Reuter; Raymond Roudaut; Jacques Clémenty; Pierre Jaïs
Journal:  J Cardiovasc Electrophysiol       Date:  2005-11

Review 4.  Systematic review of the management of atrial fibrillation in patients with heart failure.

Authors:  A U Khand; A C Rankin; G C Kaye; J G Cleland
Journal:  Eur Heart J       Date:  2000-04       Impact factor: 29.983

5.  The impact of surgical ablation in patients with low ejection fraction, heart failure, and atrial fibrillation.

Authors:  Niv Ad; Linda Henry; Sharon Hunt
Journal:  Eur J Cardiothorac Surg       Date:  2010-12-18       Impact factor: 4.191

6.  Effects of acute atrial dilation on heterogeneity in conduction in the isolated rabbit heart.

Authors:  Sabine C M Eijsbouts; Mohamed Majidi; Marc van Zandvoort; Maurits A Allessie
Journal:  J Cardiovasc Electrophysiol       Date:  2003-03

7.  Cardiac resynchronization therapy after atrioventricular junction ablation for symptomatic atrial fibrillation: a meta-analysis.

Authors:  Stavros Stavrakis; Paul Garabelli; Dwight W Reynolds
Journal:  Europace       Date:  2012-06-13       Impact factor: 5.214

8.  Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.

Authors:  Donald Lloyd-Jones; Robert Adams; Mercedes Carnethon; Giovanni De Simone; T Bruce Ferguson; Katherine Flegal; Earl Ford; Karen Furie; Alan Go; Kurt Greenlund; Nancy Haase; Susan Hailpern; Michael Ho; Virginia Howard; Brett Kissela; Steven Kittner; Daniel Lackland; Lynda Lisabeth; Ariane Marelli; Mary McDermott; James Meigs; Dariush Mozaffarian; Graham Nichol; Christopher O'Donnell; Veronique Roger; Wayne Rosamond; Ralph Sacco; Paul Sorlie; Randall Stafford; Julia Steinberger; Thomas Thom; Sylvia Wasserthiel-Smoller; Nathan Wong; Judith Wylie-Rosett; Yuling Hong
Journal:  Circulation       Date:  2008-12-15       Impact factor: 29.690

Review 9.  Rotors and spiral waves in atrial fibrillation.

Authors:  José Jalife
Journal:  J Cardiovasc Electrophysiol       Date:  2003-07

10.  Left ventricular systolic dysfunction by itself does not influence outcome of atrial fibrillation ablation.

Authors:  Tom De Potter; Antonio Berruezo; Lluis Mont; Maria Matiello; David Tamborero; Claudio Santibañez; Begoña Benito; Nibaldo Zamorano; Josep Brugada
Journal:  Europace       Date:  2010-01       Impact factor: 5.214

View more
  2 in total

1.  Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group.

Authors:  Rebabonye B Pharithi; Deepti Ranganathan; Jim O'Brien; Emmanuel E Egom; Cathie Burke; Daniel Ryan; Christine McAuliffe; Marguerite Vaughan; Tara Coughlan; Edwina Morrissey; John McHugh; David Moore; Ronan Collins
Journal:  Ir J Med Sci       Date:  2018-06-02       Impact factor: 1.568

Review 2.  Heart failure and Alzheimer's disease.

Authors:  P Cermakova; M Eriksdotter; L H Lund; B Winblad; P Religa; D Religa
Journal:  J Intern Med       Date:  2014-08-01       Impact factor: 8.989

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.